Theravance Biopharma (TBPH) announced that Viatris (VTRS), has secured regulatory approval from China’s National Medical Products Administration for Yupelri inhalation solution, the first once-daily nebulized long-acting muscarinic antagonist approved for maintenance treatment of chronic obstructive pulmonary disease in China. This approval triggers a one-time $7.5M from Viatris to Theravance Biopharma, which is expected to be received in Q3. Theravance Biopharma is also eligible for further sales-based milestones of up to $37.5M and tiered royalties of 14% to 20% on net sales in China. Viatris is responsible for all aspects of development and commercialization of Yupelri in China.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TBPH:
- Theravance Biopharma initiated with a Buy at JonesResearch
- Promising Market Opportunity for Theravance Biopharma: Buy Rating on Ampreloxetine’s Potential in MSA Treatment
- Theravance Biopharma Settles Patent Litigation with Eugia
- Theravance Biopharma’s Hold Rating: Balancing Cash Influx with Long-term Growth Uncertainty
- Theravance Biopharma’s Strategic Moves and Growth Potential Justify Buy Rating